A series of 6-(4-(4-substituted phenylpiperazin-1-yl)butoxy)benzo[d][1,3]oxathiol-2-one was synthesized. The anti-dopaminergic and anti-serotonergic activities of the synthesized compounds were evaluated as an approach to identify novel antipsychotic agent. 6-(4-(4- Substituted phenylpiperazin-1-yl)butoxy)benzo[d][1,3]oxathiol-2-ones were synthesized by reacting 6-(4-chlorobutoxy)benzo[d][1,3]oxathiol-2-one with substituted phenyl piperazines and were characterized by IR, 1H-NMR, C13-NMR, MS and elemental analysis. The antidopaminergic activity was evaluated by their ability to inhibit apomorphine induced climbing behavior and the anti-serotonergic activity of synthesized compounds was assessed by studying inhibition of 5-HTP induced head twitches in mice. The intensity of catalepsy induced by synthesised compounds was evaluated against haloperidol induced catalepsy. The pharmacological testing revealed that the compound 4l, 6-(4-(4-(2,3-dichlorophenyl)piperazin- 1-yl)butoxy)benzo[d][1,3]oxathiol-2-one and 4n 6-(4-(4-(2,3-dimethylphenyl)piperazin-1- yl)butoxy)benzo[d][1,3]oxathiol-2-one showed better antipsychotic profile with lower incidence of catalepsy induction.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report